Merck Raises 2026 Guidance After Q1 Revenue Beat, Despite $9B Deal Charge
Merck Q1 2026: $16.3B revenue beat, guidance raised. A $9B acquisition charge drove a GAAP loss, but Winrevair growth signals strong underlying fundamentals.
drug stocks Q1 2026